Autonomix Medical (AMIX) Q2 2025 earnings summary

Executive summary

• Focused on developing catheter-based technology for sensing and treating nervous system disorders, with initial application in pancreatic cancer pain management.

• No revenues reported; company remains in clinical-stage development.

• Recent licensing of FDA-cleared ablation technology and completion of a 1-for-20 reverse stock split.

Financial highlights

• Net loss of $2.8 million for the quarter and $5.5 million for the six months ended September 30, 2024, compared to $6.0 million and $6.9 million losses in the prior year periods.

• Operating expenses decreased 51% year-over-year for the quarter, primarily due to the absence of a $4.6 million warrant expense recorded in the prior year.

• Cash and cash equivalents were $5.2 million as of September 30, 2024, down from $8.6 million at March 31, 2024.

• Working capital of $4.1 million as of September 30, 2024.

Outlook and guidance

• Current cash resources are expected to fund operations into, but not beyond, the second calendar quarter of 2025.

• Additional financing of approximately $40 million will be required to reach commercialization of the first product.

• Company does not expect to generate positive cash flows from operations in the near future.